title: D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas.
abstract: Long acting D-Trp-6-luteinizing hormone-releasing hormone (LH-RH) microcapsules, 3.2 mg were given monthly, intramuscularly for a period of 6 months to 26 menstruating patients with symptomatic leiomyomas. The patients ages were 22 to 52 years. Five patients (20%) were infertile. Patient evaluation before initiation of treatment included endometrial biopsy, ultrasonic measurements of uterine and tumor volumes, and bone-mineral density. The patients were periodically followed hormonally and ultrasonographically. A statistically significant reduction in uterine and tumor volumes (maximal after 4 months of treatment) was observed in all the patients except one. Two patients discontinued the treatment after 2 months, preferring surgery. A nonsignificant decrease in the mean bone-mineral density was noted after completion of therapy. Minor side effects such as hot flushes, vaginal dryness, backache, vaginal spotting, and nervousness, were encountered frequently, disappearing within 6 weeks after the last injection. A significant increase in uterine and myoma volume was noted in all the patients at 3 months after treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Assaf Harofe Medical Centre, Zerifin, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Golan
authors.forename: I
authors.initials: I
authors.lastname: Bukovsky
authors.forename: D
authors.initials: D
authors.lastname: Schneider
authors.forename: R
authors.initials: R
authors.lastname: Ron-el
authors.forename: A
authors.initials: A
authors.lastname: Herman
authors.forename: E
authors.initials: E
authors.lastname: Caspi
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002214:Capsules; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D007889:Leiomyoma / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D013997:Time Factors; D017329:Triptorelin Pamoate; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D002214:Capsules; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone